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Fibromyalgia (FM), characterized by chronic widespread pain, fatigue, and cognitive/mood disturbances, leads to reduced work-
place productivity and increased healthcare expenses. To determine if acquired epigenetic/genetic changes are associated with FM,
we compared the frequency of spontaneously occurring micronuclei (MN) and genome-wide methylation patterns in women with
FM (𝑛 = 10) to those seen in comparably aged healthy controls (𝑛 = 42 (MN); 𝑛 = 8 (methylation)). The mean (sd) MN frequency
of women with FM (51.4 (21.9)) was significantly higher than that of controls (15.8 (8.5)) (𝜒2 = 45.552; df = 1; 𝑃 = 1.49 × 10−11).
Significant differences (𝑛 = 69 sites) in methylation patterns were observed between cases and controls considering a 5% false
discovery rate. The majority of differentially methylated (DM) sites (91%) were attributable to increased values in the women
with FM. The DM sites included significant biological clusters involved in neuron differentiation/nervous system development,
skeletal/organ system development, and chromatin compaction. Genes associated with DM sites whose function has particular
relevance to FM included BDNF, NAT15, HDAC4, PRKCA, RTN1, and PRKG1. Results support the need for future research
to further examine the potential role of epigenetic and acquired chromosomal alterations as a possible biological mechanism
underlying FM.
1. Introduction
Fibromyalgia (FM), which affects at least 10millionAmerican
adults [1], is a multisymptom condition resulting in not only
widespread chronic pain, but also fatigue, sleep disturbances,
and morning stiffness. In addition, many patients experience
depression, anxiety, and dyscognition [2, 3]. FM has a
significant adverse impact on many individuals’ physical and
mental health [4, 5] and also leads to reduced workplace pro-
ductivity and increased health care/disability expenses, with
the estimated cost of FM on the US economy being reported
to be 12–14 billion dollars [1, 6]. While the adverse impact of
this condition is indisputable, its etiology remains enigmatic.
Due to the lack of clarity for the underlying cause(s) of
FM, it poses a diagnostic challenge, often requiring multiple
visits by specialists to render a diagnosis [7]. The lack
of understanding of the biological basis of this condition
also confounds our ability to develop effective interventions
and/or monitor disease progression. FM has been suggest-
ed to be a complex, multifactorial trait that is influenced by
age, gender (frequency is the highest in middle-aged fe-
males), and stress/trauma. Despite showing a strong famil-
ial aggregation [8–10], attempts to identify genetic fac-
tors associated with FM (primarily through polymorphism
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association studies) have yielded inconsistent results, with
some investigators showing associations between FM and
specific genes (including, but not limited to, genes for
catechol-O-methyltransferase [11–13], serotonin-2A receptor
[14, 15], serotonin transporter gene regulatory region [16, 17],
dopamine D4 receptor [18], 𝛽-2 adrenergic receptor [19],
gamma-aminobutyric acid receptor subunit beta-3, trace
amine-associated receptor 1, interferon-induced guanylate-
binding protein 1, regulator of G protein signaling 4, cannabi-
noid receptor type 1, and glutamate receptor 4 [20]), while
others failed to identify a relationship [21–25]. Since a con-
sistent, straightforward association with a gene(s) has not yet
been forthcoming, scientists have suggested that the familial
influence on FMmaymore likely reflect a genetic susceptibil-
ity to environmental events [21, 26, 27]. For example, Klengel
and Binder [28] identified differential methylation for a glu-
cocorticoid response element (the FKBP5 gene) that resulted
from the presence of both an “at-risk” allele (polymorphism)
and the occurrence of childhood trauma in subjects they
studied who had posttraumatic stress disorder.
Epigenetics, which refers to the process that affects gene
expression independent of actual DNA sequence (such as
methylation changes, histone alterations, and micro-RNA
expression), has enabled scientists to conceptualize the
impact of the environment upon one’s genes and one’s health
[29]. Genes can be turned on or off and display variations
in their level of expression, in part, due to epigenetic mod-
ifications [30]. Thus, epigenetics provides a biological means
for understanding the molecular processes of complex bio-
logical networks that connect the brain, behavior, and health
outcomes [31]. Given the overlap in symptoms and the
medical/adverse social histories present in people who have
FM, when compared to other conditions that have been
shown to be impacted by somatic epigenetic and genetic
alterations (such as depression and stress), it is plausible that
similar epigenetic mechanisms may underlie the individual
variability in the outcome of genetic and emotional inputs for
FM.
Knowing that histone and other epigenetic modifications
play a key role in establishing and maintaining chromatin
structure, it follows that changes in epigenetic profiles, as a
consequence of initiating events (such as stress/environmen-
tal exposure), could also lead to an increased frequency of
somatic chromosomal changes. Indeed, we have shown that
stress levels can impact the frequency of acquired chromoso-
mal abnormalities by demonstrating a significantly increased
frequency of somatic cell chromosomal instability in adult
women who experienced childhood sexual abuse when
compared to their identical cotwins who did not experience
childhood sexual abuse (quantified using a micronucleus
assay) [32]. Further support that chromosomal instability
could arise as a downstream effect following perturbations
in methylation comes from studies of individuals who have
immunodeficiency, centromeric region instability, and facial
anomalies (ICF) syndrome, which is an autosomal recessive
condition resulting from a mutation in the methyltransferase
gene B. People with this condition have an increased fre-
quency of acquired chromosomal abnormalities [33].
An efficient means for quantifying the frequency of
acquired (somatic) chromosomal abnormalities is the cytoki-
nesis block micronucleus (CBMN) assay, which provides
information regarding the presence of chromosomal errors in
somatic cells with minimal influences attributable to in vitro
selective growth pressures [34]. This technique is less labor
intensive than conventional cytogenetic studies but provides
results that are in close agreement to those obtained using
the “gold standard” ofmetaphase chromosomal analyses [35].
Micronuclei, which are the primary cytological structures
scored in the CBMN assay, are thought to contain chromatin
(from one or more chromosomes) that was not incorporated
(“lagging” or “lost”) into the daughter binucleates following
nuclear division [34]. Micronuclei frequencies have been
shown to increase with age and have been associated with
a variety of health conditions [36, 37]. However, to date, no
investigators have reported the frequency of MN in women
with FM. Based on the symptomatology and comorbidities
related to this condition, we hypothesized that women with
FM will have an increased frequency of acquired epigenetic
and chromosomal alterations. To test this hypothesis, we
initiated a pilot study to quantify chromosomal instability
levels and genome-wide methylation patterns in women
having FM and to compare these genetic/epigenetic values to
those present in comparably aged, healthy control women.
2. Materials and Methods
2.1. Study Participant Ascertainment and Specimen Collection.
Data for this studywere obtained froma subset of participants
(𝑛 = 10), who were randomly recruited by mail from a
larger, parent study sample of 64 women diagnosed with
fibromyalgia (VCU IRBProtocol numberHM12211) (Table 1).
In the parent study, the participants completed a two-
group randomized, controlled, clinical trial to examine the
effect of guided imagery on self-efficacy, perceived stress,
pain, fatigue, depression, and neuroendocrine/neuroimmune
biomarkers in women with fibromyalgia syndrome [38].
Inclusion criteria for the women having FM were age (at
least 18 years old); gender (female); receipt of a physician-
confirmed diagnosis of FM based on the 1990 American Col-
lege of Rheumatology criteria [39]; an ability to understand
and sign the consent form; and an ability to understand/
complete the study questionnaires. Exclusion criteria for the
women in the FM pilot group included the presence of other
systemic rheumatologic conditions; being immunocompro-
mised (e.g., diagnosis of HIV/AIDs); receiving corticosteroid
treatments; having a major psychiatric or neurological con-
dition that would interfere with study participation, or being
pregnant. Each of the study subjects completed a self-report
form to provide information regarding age, race/ethnicity,
marital status, length of time since diagnosis of fibromyalgia,
height andweight for calculating bodymass index (BMI), and
lifestyle practices such as history of smoking and alcohol use.
The healthy, comparatively aged control group of women
for the MN studies (𝑛 = 42) were ascertained through their
participation in a study of acquired genetic changes associ-
ated with normal aging, the latter of which is a twin study
[40] (VCU IRB Protocol number 179). The inclusion criteria
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Table 1: MN frequencies and other attributes of women with FM.
Participants
with FM Age
Mean number MN
per 1000 binucleates
Years since FM
diagnosis Alcohol use Smoker Body mass index Race
1009 48 32.5 2 Yes No 45.7 Other
1025 52 13.5 3 Yes Yes 19.4 C1
1030 61 71 7 No No 28.3 C
1038 52 66.5 19 No No 35.5 C
1042 45 47.5 14 No No 30.1 AA2
1047 62 77.5 19 Yes No 27.1 C
1052 44 42 1 Yes Yes 30.5 AA
1058 45 27.5 4 No No 27.3 AA
1061 58 66.5 2 Yes Yes 21.1 C
1066 56 69.5 4 Yes Yes 29.0 AA
FM group mean (sd)
(𝑛 = 10) 48.2 (6.7) 52.1 (21.9) 29.52 (7.21)
Control group mean (sd)
(𝑛 = 42)∗ 52.0 (9.8) 15.8 (8.5)
∗Individual data not shown.
1C: Caucasian (white); 2AA: African American (Black).
for this subset of control subjects were gender (female) and
age (range from 36 to 69 years old), with all people from
the previous study who met the criteria being included as
controls for the current study to avoid sampling biases. The
control cohort of women included both cotwin pairs (𝑛 = 30
women or 15 cotwin pairs) and single twins, whose cotwin
did not participate in this normal aging study (𝑛 = 12
women). Due to cost limitations, DNA methylation studies
were limited to a subset (𝑛 = 8) of the control women.
This subset of women was randomly selected and included
8 unrelated females (no cotwins). All of the control women
self-reported their age, race/ethnicity, and lifestyle practices,
such as history of smoking and alcohol use.
2.2. Biological Assays. Following the collection of the blood
specimens from the patient and control women, the cells were
processed to obtain binucleates for the micronuclei studies
and DNA for the methylation studies as described in the
following section.
2.2.1. Micronucleus Assay. Lymphocytes were collected using
Histopaque-1077 (Sigma), stimulated with the mitogen phy-
tohemagglutinin, established in culture, and blocked at
cytokinesis according to the protocol of Fenech [35]. Briefly,
cytochalasin B (3.0 𝜇g/mL; Sigma, 14930-92-2) was added to
the cells 44 hours after culture initiation. At 72 hours, binucle-
ate interphase cells were harvested using standard techniques,
which included a 10-minute incubation in hypotonic solution
(0.075M KCl) and serial fixation (three times using a 3 : 1
methanol : acetic acid solution). Slides were made following
standard procedures. Micronuclei were visualized following
Giemsa staining (4%HarlecoGiemsa solution) and identified
according to the criteria established by Fenech [35] (Figure 1).
The frequencies of micronuclei observed in the cytochalasin-
B-blocked binucleated cells of the women with FM and the
healthy control women were calculated by averaging the
values obtained from two replicate scores (1000 binucleates
were evaluated from two independent areas of the slide) for a
total of 2000 binucleates thatwere evaluated per study partici-
pant.
2.2.2. DNA Isolation and Genome-Wide Methylation Assay.
Genomic DNA was isolated from whole blood according
to standard methods using the Puregene DNA isolation kit
(Qiagen). An aliquot (500 ng per study participant) of DNA
was then sent to Hudson Alpha Institute for Biotechnology
for bisulfite conversion, using standard methods (Zymo
Research EZ Methylation Kit) and genome-wide methyla-
tion pattern assessment, using the 450K HumanMethylation
Chip, according to the manufacturer’s protocol (Illumina).
The 450K HumanMethylation Chip interrogates 485,764
genome-wide targets. Intensity data from the scanned arrays
were imported into Illumina’s GenomeStudio software and
theminfi Bioconductor package in the R programming envi-
ronment to obtain the 𝛽 values for each probe.
2.3. Statistical Analyses
2.3.1. Micronuclei Analyses. To test the hypothesis that
women with FM have an increased frequency of acquired
chromosomal alterations, the frequency of MN was com-
pared between the women diagnosed with FM and the
control group women. Given that a portion of the healthy
controls were cotwins, a mixed effect model was used to
control for familial relationships.MN frequency comparisons
between cases and controls were adjusted for age since several
studies have demonstrated increases in MN frequency with
age [37, 40–42]. The independent effect of age on MN was
evaluated using a Spearman correlation. Additional environ-
mental effects were considered that have previously been
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Figure 1: Increased frequency of micronuclei (MN) in women with FM. (a) A representative cell blocked at the cytokinesis phase of mitosis is
shown. Karyokinesis has been completed, resulting in 2 daughter binucleates having a single MN (arrow). (b) The frequency of MN (𝑦-axis)
showed the expected age-related increase (age on 𝑥-axis) for both controls (Spearman’s rho = 0.579) and patients having FM (Spearman’s
rho = 0.717). The least squares regression line with corresponding 95% confidence interval (grey region) is shown for each group. After
controlling for age effects, the frequencies of MN were found to be significantly higher in the women with FM compared to healthy controls
(𝑃 = 1.49 × 10−11).
shown to influence micronuclei frequencies. These included
body mass index, alcohol use, and smoking in the women
having FM [40]. However, given that values for body mass
index, alcohol use, and smoking were not available for the
controls (in a format comparable to those for cases), these
variables were only assessed for the women with FM.
2.3.2. Genome-WideMethylationAnalyses. Because the 450K
HumanMethylation assay includes both the Infinium I design
(which includes two probes for interrogating a CpG site) and
the Infinium II design (which includes only one probe), the
GC content was plotted separately by Infinium design type
for the fully methylated sample, for which all CpG sites are
expected to have consistently high 𝛽 values [43]. Based on
these results, probes having a GC content greater than 40
were excluded from further analysis to ensure that the results
would not be biased by the “GC” content of the underlying
sequence. In addition, since the performance of probes
containing single nucleotide polymorphisms (SNPs) can be
variable, probes containing SNPs that were present within 10
bases of the target site were also excluded [43]. Because the
expression value, 𝛽, reported for each CpG site represents
“proportion methylated” which is constrained to an interval
value from 0 to 1, where a 𝛽 of 1 indicates complete
methylation and 0 indicates no methylation, the expression
values were transformed using the logit transformation
[𝑀 = log(𝛽/(1 − 𝛽)] to promote normality [44]. Prior to the
logit transformation, imputation was completed (0.001 for
𝛽 values that were 0 and 0.999 for 𝛽 values that were 1) to
avoid nonexistent 𝑀 values. To adjust for the observation
that 𝛽 values from the Infinium II designed probes have a
compressed range compared to the 𝛽 values from the Infini-
um I design [43, 45, 46], the peak-correction method was
applied to the logit transformed 𝛽 values for the Infinium II
designed probes [46].
Statistical analyses were then performed on the peak
corrected logit transformed 𝛽 values from the patient and
control samples. For each CpG site, differential methylation
between specimens collected from women with FM and
controls was tested using the moderated 𝑡-test in the limma
Bioconductor package [51, 52] in the R programming envi-
ronment [53]. To adjust for the multiple hypothesis tests,
the 𝑃 values were used to estimate the false discovery rate
(FDR) following Benjamini and Hochberg’s [54] method.
The DAVID gene functional classification tool [55] was used
to identify biological relationships among the differentially
methylated sites.
3. Results
3.1. Micronucleus Assay. As expected, the frequency of MN
was correlated with age in both the women having FM
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Table 2: Genes associated with sites differentially methylated in patients with fibromyalgia.
Gene name (abbreviation) Description of function1 Location2
AXL receptor tyrosine kinase (AXL) Involved in stimulation of cell proliferation and aggregation; induced
by TGF-𝛽1/inflammation; and can block cytokine production 19: 41731934
N-Acetyltransferase 15 (NAT15) Histone acetyltransferase; mediates acetylation of free histone H4;also required for normal chromosomal segregation during anaphase 16: 3507460
Solute carrier family 17, member 9
(SLC17A9)
Vesicular nucleotide transporter involved in exocytosis of ATP in
secretory vesicles (synaptic vesicles) 20: 61584072
Brain-derived neurotrophic factor (BDNF)
Involved in the regulation of stress response and in the biology of
mood disorders; major regulator of synaptic transmission and
plasticity at adult synapses in many regions of the CNS; contributes to
several adaptive neuronal responses including long-term potentiation,
long-term depression, certain forms of short-term synaptic plasticity,
and homeostatic regulation of intrinsic neuronal excitability
11: 27740495
Mahogunin ring finger 1, E3 ubiquitin
protein ligase (MGRN1)
Mediates monoubiquitination at multiple sites; plays a role in the
regulation of endosome-to-lysosome trafficking. 16: 4714733
Plasma glutamate carboxypeptidase (PGCP) Involved in hydrolysis of circulating peptides 8: 97657294
Protein kinase C, alpha (PRKCA)
Involved in diverse cell signaling pathways; activated by calcium;
associated with cancer; posttraumatic stress syndrome; emotional
memory formation; and aging
17: 64787379
Gamma-glutamyltransferase 1 (GGT1) Function not clear and may vary; has been associated with arterialstiffness and coronary artery disease [47] 22: 24989248
Reticulon 1 (RTN1) Involved in secretion or membrane trafficking in neuroendocrinecells; associated with neurological diseases and cancer 14: 60097209
NFXL1 nuclear transcription factor, X-box
binding-like 1 (NFXL1) Integral to the nucleus and membrane 4: 47917042
Heat shock 70 kDa protein 8 (HSPA8) Member of the heat shock protein family, functions as a chaperoneand facilitates protein folding 11: 122933028
Polymeric immunoglobulin receptor (PIGR) Member of the immunoglobulin superfamily that facilitatesexpression of immunoglobulins A and M; regulated by cytokines 1: 207103660
Benzodiazepine receptor (peripheral)
associated protein 1 (BZRAP1) An adaptor molecule known to regulate synaptic transmission [48] 17: 56401800
Transmembrane protein 91 (TMEM91) In vivo function not clearly established 19: 41882253
Neuron-derived orphan receptor 1 (NR4A3) Target of 𝛽-andrenergic signaling in skeletal muscle [49] 9: 102588232
V-set and immunoglobulin domain
containing 10 (VSIG10) In vivo function not clearly established 12: 118541722
Potassium voltage-gated channel subfamily
H member 7 (KCNH7)
Involved in regulating neurotransmitter release, heart rate, insulin
secretion, neuronal excitability, epithelial electrolyte transport,
smooth muscle contraction, and cell volume.
2: 163695111
V-set and transmembrane domain
containing 2A (VSTM2A) In vivo function not clearly established 7: 54609587
Ephrin type-A receptor 2 (EPHA2) Protein-tyrosine kinase family member; implicated in mediatingdevelopmental events, particularly in the nervous system. 1: 16482553
Patched 2 (PTCH2)
A transmembrane receptor of the patched gene family; may function
as a tumor suppressor in the hedgehog signaling pathway; has been
associated with several different types of cancer
1: 45297445
Histone deacetylase 4, (HDAC4)
Responsible for the deacetylation of the core histones; gives tag for
epigenetic repression; plays important role in transcriptional
regulation, cell cycle progression, and developmental events; also
involved in muscle maturation through interaction with the myocyte
enhancer factors
2: 240044021
ADP-ribosylarginine hydrolase (ADPRH) Catalyzes removal of mono-ADP-ribose from arginine residues ofproteins in the ADP-ribosylation cycle. 3: 119299162
Fasciculation and elongation protein zeta 1
(zygin I) (FEZ1)
Involved in normal axonal bundling and elongation within axon
bundles; may also function in axonal outgrowth. 11: 125365478
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Table 2: Continued.
Gene name (abbreviation) Description of function1 Location2
Superoxide dismutase 3, extracellular
(SOD3)
Antioxidant enzyme thought to protect the brain, lungs, and other
tissues from oxidative stress. 4: 24801801
Transcription factor AP-2 alpha 2 (TFAP2A) Transcription factor; activates the transcription of some genes whileinhibiting the transcription of others 6: 10420079
Odz, odd Oz/ten-m homolog 3 (ODZ3) May function as a cellular signal transducer 4: 183370512
Ephrin type A receptor 5 (EPHA5)
Mediates developmental events, particularly in the nervous system;
plays a role in synaptic plasticity in adult brain through regulation of
synaptogenesis; also mediates communication between pancreatic
islet cells to regulate glucose-stimulated insulin secretion
4: 66535145
Suppressor of fused homolog (Drosophila)
(SUFU)
Plays a role in pattern formation and cellular proliferation during
development; encodes a negative regulator of the hedgehog signaling
pathway
10: 104393081
Rh family, C glycoprotein (RHCG) Functions as an electroneutral and bidirectional ammoniumtransporter 15: 90039613
DNAJ (Hsp40) homolog, subfamily C,
member 17 (DNAJC17) Heat shock protein homolog 15: 41062113
Autism susceptibility candidate 2 (AUTS2) Function not fully known; deletions of this gene have been associatedwith autism and intellectual disability 7: 70158761
Deleted in lymphocytic leukemia, 7
(DLEU7) In vivo function not clearly established 13: 51417846
SH2B adaptor protein 2 (SH2B2)
Involved in multiple signaling pathways; may function as a negative
regulator of cytokine signaling; suppresses PDGF-induced
mitogenesis: may induce cytoskeletal reorganization via interaction
with VAV3
7: 101934892
Alpha-kinase 3 (ALPK3) Recognizes phosphorylation sites (alpha-helical conformation); mayplay a role in cardiomyocyte differentiation 15: 85360691
VENT homeobox (VENTX) May function as a transcriptional repressor and influencemesodermal patterning and hemopoietic stem cell maintenance 10: 135050326
Lymphocyte antigen 6 complex, locus G5C
(LY6G5C)
Located in the major histocompatibility complex (MHC) region on
chromosome 6; may be involved in signal transduction or
hematopoietic cell differentiation
6: 31649619
Primary ciliary dyskinesia protein 1 (PCDP1) May function in ciliary motility 2: 120301847
Protein kinase, cGMP-dependent, type I
(PRKG1)
Involved in signal transduction processes in diverse cell types; plays
role in regulating cardiovascular and neuronal functions and in
relaxing smooth muscle tone, preventing platelet aggregation, and
modulating cell growth
10: 52833610
MAP7 domain containing 2 (MAP7D2) X-linked imprinted gene that may affect sex-specific brain functionand/or sex-dependent neurobiological traits [50] X: 20134719
Carboxypeptidase M (CPM)
Associated with monocyte to macrophage differentiation; may play
role in control of peptide hormone and growth factor activity at the
cell surface and in the membrane-localized degradation of
extracellular proteins
12: 69346994
Growth differentiation factor 1
(GDF1)/LAG1 longevity assurance homolog
1 (LASS1)
Member of TGF-beta superfamily; may function in regulation of cell
growth and differentiation in embryonic and adult tissues and neural
development in later embryogenesis; may be involved in aging
19: 18981378
Ubiquitin-like, containing PHD and RING
finger domains, 1 (UHRF1)
Recruits a histone deacetylase to regulate gene expression; involved in
G1/S transition and functions in the p53-dependent DNA damage
checkpoint
19: 4916593
Anoctamin 3 (AN03) May act as a calcium-activated chloride channel 11: 26353723
Homeobox protein Hox-A7 (HOXA7) DNA-binding transcription factor that may regulate gene expression,morphogenesis, and differentiation 7: 27196790
Transmembrane protein 44 (TMEM44) Enriched in the bottom portion of taste buds 3: 194353554
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Table 2: Continued.
Gene name (abbreviation) Description of function1 Location2
Potassium voltage-gated channel, KQT-like
subfamily, member 1 (KCNQ1)
Voltage-gated potassium channel required for repolarization phase of
the cardiac action potential; mutations associated with hereditary
long QT syndrome 1, the Jervell and Lange-Nielsen syndrome, and
familial atrial fibrillation; exhibits tissue-specific imprinting; located
in a region associated with the Beckwith-Wiedemann syndrome
11: 2554583
Polymerase I and transcript release factor 1
(PTRF)
Regulates rRNA transcription; thought to modify
lipid metabolism and insulin-regulated gene expression 17: 40558063
1Functional descriptions obtained from Gene Cards and/or Wikipedia summations and indicated references.
2Chromosome: starting nucleotide position.
Table 3: Cluster analysis of genes having significantly different methylation patterns in women with FM.
Genetic ontology/keyword term No. of Genes 𝑃 value
Anatomical structure development 17 0.0002
System development 16 0.0003
Developmental process 18 0.0008
Multicellular organismal development 17 0.0009
Polymorphism 41 0.0011
Sequence variant 42 0.0012
Domain: fibronectin type III 1, 2 4 0.0045
Glycosylation site 20 0.0047
Neuron differentiation 6 0.0048
Nervous system development 9 0.0053
Protein metabolic process 15 0.0067
Autophosphorylation 3 0.0069
Glycoprotein 20 0.0073
Skeletal system development 5 0.0085
Organ development 11 0.0097
(𝑟 = 0.717; 𝑃 = 0.021) and the healthy controls (𝑟 = 0.579;
𝑃 = 4.79 × 10
−5) (Figure 1). After controlling for the effect
of age and cotwin status, a significantly increased frequency
of MN was observed in the women having FM (51.4 (21.9)
(mean (sd)) per 1000 binucleates) compared to controls (15.8
(8.5) (mean (sd)) per 1000 binucleates) (𝜒2 = 45.6; df = 1;
𝑃 = 1.49 × 10
−11) (Figure 1). The increased levels of MN in
the women having FM were not significantly correlated with
their body mass index (range from 19.44 to 45.70; mean (sd)
was 29.52 (7.21); 𝑃 = 0.997), smoking history (4 smokers;
6 nonsmokers; 𝑃 = 0.75), or alcohol use (6 consumers;
4 nonconsumers; 𝑃 = 0.93). To assess if there might be
a cumulative biological effect associated with experiencing
symptoms associatedwith FM,we comparedMN frequencies
for the case subjects (𝑛 = 10) with the total number of years
that had lapsed since these women received their diagnosis
of FM. While there was a trend toward a positive correlation
between a woman’s MN frequency and the number of years
since she was diagnosed with FM (ranged from 2 to 19 years),
this relationship did not reach significance in this small pilot
study (𝑃 = 0.134) (Table 1).
3.2. Genome-Wide Methylation Assay. After completion of
the quality control assessments that were performed to
remove any potential biases associated with probe sequence
length, probe GC content, and inclusion of SNPs [56], a total
of 381,989 CpG sites were retained. From these, a total of 69
sites were determined to be differentially methylated (DM)
between the patients who have FM and the healthy controls,
with 63 of these DM sites having higher values in the patients
with FM and 6 having lower values (Figure 2). These 69 DM
sites included CpG islands (46.4%); north shores (20.3%);
south shores (8.7%); as well as north (4.3%) and south (1.4%)
shelves and sites that were not annotated into the previously
noted categories (18.8%). The DM sites were localized to
47 different genes (Table 2), with 3 genes having multiple
sites identified (N-acetyltransferase 15 gene (NAT15) had 4
DM sites; DNAJ (Hsp40) homolog, subfamily C, member 17
(DNAJC17) had 2 DM sites; and SLC17A9 and 2 DM sites).
An assessment of potential biologically related clusters of
DM sites resulted in the recognition of 15 groups, including
gene clusters involved in neuron differentiation and nervous
system development (Table 3).
4. Discussion
While the sample size in this pilot study is small, the MN
frequency patterns of both the case and control women
showed an age-related increase, which is a finding that is in
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Figure 2: Sites having significantly different methylation patterns in women with FM compared to healthy controls. (a) A heatmap shows the
69 DM sites detected in the study. The women who have FM (F) are grouped on the left of the figure, with controls (C) being grouped on the
right. Each row (CpG site) is scaled to represent methylation where lower levels are represented in green while higher levels are represented
in red.Themajority of significant differences resulted fromwomen with FM (upper left red cluster) having higher levels compared to controls
(upper cluster), with a smaller cluster (lower left green) showing lower methylation levels in the cases with FM compared to healthy controls.
(b) Pie charts showing the percentage of DM sites according to their relationship to CpG islands. Nearly half (46.4%) of the sites that were
significantly different between the women with FM compared to controls were localized to CpG islands (top pie chart), whereas CpG islands
account for only about one third (31%) of the sites interrogated on the 450K HumanMethylation array (bottom pie chart). The proportion
of DM sites localized to shores that were recognized in this study (29%) closely paralleled the proportion of sites localized to shores that are
interrogated in the array (23%). Sites associated with a location distant to CpG islands accounted for 24.5% of the DM sites identified in this
study but accounted for 46% of the total sites interrogated on the array.
agreement with the age-related increase that has consistently
been reported in larger studies [40, 41]. Interestingly, the
mean frequency of MN in the women with FM was 3.26-
fold higher than the level seen in the healthy controls. In
comparison, patients who have cancer have been noted
to have 1.37- to 3.13-fold higher frequencies of MN when
compared to healthy controls [57, 58]. Given that the risk for
cancer has been shown to be predicted by MN levels [37, 41,
58], the results of this preliminary data, if confirmed, suggest
that MN frequency assessments may be useful for evaluat-
ing/diagnosing women with FM. Indeed, recent assessments
of MN frequencies in people evaluated from various areas of
biobehavioral science have shown increased levels of acquired
chromosomal instability (assessed using MN frequencies) in
adult women who experienced childhood sexual abuse [32];
patients who have neurodegenerative conditions, such as
Alzheimer’s disease and Parkinson’s disease [59]; and adults
with type 2 diabetes and cardiovascular disease [60]. The
presence of acquired chromosomal instability, which could
lead to somatic tissue mosaicism, has been conjectured to
occur as a global biological process that affects many tissues
and contributes to the development of several conditions,
including (but not limited to) autism, schizophrenia, autoim-
mune diseases, and Alzheimer’s disease [61]. Given that
several of these conditions are age related, one could speculate
that there may be a “threshold” level of chromosomal insta-
bility required for eliciting a biological consequence. Factors
contributing to MN formation are multifold and include
both genetic [40] and environmental influences [37, 40, 41].
Environmental exposures that have been shown to increase
the frequency of MN include, but are not limited to, diet
(especially folate deficiency) [41, 62, 63], hormone levels
[64], and exposures to substances/occupational hazards [37].
The biological means whereby these genetic/environmental
influences lead to acquired chromosomal instability are likely
to be varied but have been noted to reflect the chromatin
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conformation of the chromosomes [65]. One can speculate
that alterations in chromatin conformation, which are likely
to arise (at least in part) from epigenetic changes, may com-
promise the ability of the chromosomes to align, attach to
mitotic spindle fibers, and/or separate, thereby leading to
their increased frequency of abnormalities [66]. In turn, the
presence of acquired chromosomal abnormalities could lead
to additional epigenetic alterations.
While limited in number, studies performed to assess
the effect of methylation on chromosome segregation have
consistently shown an increase in the frequency of cytogenic
abnormalities associated with perturbations in the methyla-
tion status of chromosomes [67]. In this study, it is interesting
to note that DM sites were identified for genes having a
function related to chromatin compaction and/or segregation
(NAT15; HDAC4; UHRF1). For example, DM sites were
observed for the NAT15 gene, which is a gene that has been
identified to play an important role in normal chromosomal
segregation during anaphase [68]. While the results of the
genome-wide methylation patterns evaluated in this study
are preliminary, it is exciting to note that several of the sites
that were DM between the women with FM and controls
were localized to genes that have functional relevance to the
symptoms seen in patients with FM. Of particular interest
was the observation of a significant difference in the methy-
lation pattern of the BDNF gene between patients with FM
and controls. The BDNF gene has been noted to play an
important neuromodulatory role in pain transduction (elic-
iting hyperalgesia) [69–71] and has also been recognized as a
contributor to learning and memory [72, 73]. A second gene
of apparent relevance with which a DM site was associated
was the protein kinase C, alpha gene (PRKCA) (Table 3).This
gene, which is involved in cell signaling pathways, has been
associated with emotional memory formation, posttraumatic
stress syndrome, cancer, and aging. A third gene of particular
interest that had a DM site is Reticulon 1 (RTN1). RTN1 has
been associated with neurological diseases (and cancer) and
is thought to influence membrane trafficking in neuroen-
docrine cells. Overall, genes with which DM sites were asso-
ciated include (but are not limited to) those having functions
in chromatin compaction (NAT15; HDAC4; UHRF1); DNA
damage/repair or chromosomal segregation (SOD3; UHRF1;
NAT15);muscle contraction (NR4A3;HDAC4; FEZ1; PRKG1;
KCNH7); axonal bundling/outgrowth (FEZ1); cell signaling
in muscle (NR4A3; PRKG1); neuronal excitability/synaptic
transmission (BDNF; BZRAP1; EPHA5; KCNH7); muscle
maturation (HDAC4); response to oxidative stress (SOD3);
and inflammatory processes (AXL; SH2B2). However, since
two of the significant biological clusters that were identified
(Table 3) were for polymorphisms and sequence variants, it
is important to recognize that this is a pilot study and that
a larger number of individuals will need to be evaluated
to allow one to determine the extent, if consistently present, of
DM on the development or severity of symptoms associated
with FM.
The results of genome-wide methylation studies have
provided insight regarding the role of genes and environ-
mental influences for a variety of conditions, with many of
these investigations focusing on the areas of cancer and
psychiatric conditions [74, 75]. However, the epigenomes
of diseases causing chronic pain have been less extensively
evaluated. In their study of rheumatoid arthritis, Nakano
et al. [76] observed several DM sites between patients who
have rheumatoid arthritis and controls. They also identified
distinct epigenomic signatures when comparing patterns
from patients with rheumatoid arthritis and osteoarthritis.
Akin to the results of this pilot study, the findings of their
investigation led to the recognition of perturbations in the
methylation status of several genes having functions related
to the symptoms associated with rheumatoid arthritis. Thus,
the use of genome-wide epigenetic assessment seems to be a
promising tool for evaluating a broad spectrumof conditions,
including those associated with chronic pain.
5. Conclusion
In summary, the results of this pilot study suggest that
chromosomal instability and alterations in methylation are
present in women with FM. If these results can be confirmed,
they could provide a basis for improving our understanding
of the biological changes leading to the development of FM
and may provide a basis for stratifying patients based on
their epigenomic and symptompatterns.Moreover, since epi-
genetic changes demonstrate plasticity [77], the recogni-
tion of consistent epigenetic alterations associated with FM
could provide a means for developing future therapeutic
approaches to reverse these changes, with a goal of alleviating
symptoms in people who have FM.
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